Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Payables (2021 - 2026)

Indivior Pharmaceuticals has reported Payables over the past 6 years, most recently at $178.0 million for Q1 2026.

  • For Q1 2026, Payables fell 2.73% year-over-year to $178.0 million; the TTM value through Mar 2026 reached $178.0 million, down 2.73%, while the annual FY2025 figure was $250.0 million, 15.74% up from the prior year.
  • Payables for Q1 2026 was $178.0 million at Indivior Pharmaceuticals, down from $250.0 million in the prior quarter.
  • Over five years, Payables peaked at $620.0 million in Q4 2022 and troughed at -$815.0 million in Q3 2024.
  • A 5-year average of -$132.7 million and a median of $183.0 million in 2025 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 68.06% in 2023 and later skyrocketed 126.38% in 2025.
  • Year by year, Payables stood at $620.0 million in 2022, then crashed by 68.06% to $198.0 million in 2023, then increased by 9.09% to $216.0 million in 2024, then rose by 15.74% to $250.0 million in 2025, then dropped by 28.8% to $178.0 million in 2026.
  • Business Quant data shows Payables for INDV at $178.0 million in Q1 2026, $250.0 million in Q4 2025, and $215.0 million in Q3 2025.